Welch & Forbes LLC trimmed its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 1.0% in the third quarter, Holdings Channel reports. The institutional investor owned 79,456 shares of the medical instruments supplier’s stock after selling 808 shares during the period. Welch & Forbes LLC’s holdings in Becton Dickinson and were worth $20,739,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the company. FMR LLC boosted its stake in shares of Becton Dickinson and by 13.7% during the 2nd quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock worth $4,069,559,000 after buying an additional 2,049,874 shares during the last quarter. Fundsmith Equity Fund L.P. acquired a new position in shares of Becton Dickinson and during the 2nd quarter worth about $894,775,000. Putnam Investments LLC boosted its stake in shares of Becton Dickinson and by 0.5% during the 2nd quarter. Putnam Investments LLC now owns 3,513,485 shares of the medical instruments supplier’s stock worth $841,690,000 after buying an additional 18,859 shares during the last quarter. Fiera Capital Corp boosted its stake in shares of Becton Dickinson and by 1.7% during the 2nd quarter. Fiera Capital Corp now owns 2,801,767 shares of the medical instruments supplier’s stock worth $671,192,000 after buying an additional 46,111 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Becton Dickinson and by 0.6% during the 2nd quarter. Bank of America Corp DE now owns 2,766,688 shares of the medical instruments supplier’s stock worth $662,788,000 after buying an additional 15,603 shares during the last quarter. Institutional investors own 92.51% of the company’s stock.
A number of equities analysts have recently commented on the stock. Morgan Stanley increased their price objective on shares of Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 4th. Wells Fargo & Co upped their target price on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Citigroup upped their target price on shares of Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $248.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Finally, KeyCorp reaffirmed a “buy” rating and issued a $264.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $255.40.
Becton Dickinson and stock traded down $0.51 during trading hours on Wednesday, hitting $243.79. The company had a trading volume of 8,359 shares, compared to its average volume of 1,161,953. The stock has a market cap of $69.83 billion, a P/E ratio of 25.86, a P/E/G ratio of 1.78 and a beta of 1.11. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. Becton Dickinson and Co has a one year low of $200.08 and a one year high of $265.87.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.86 by $0.05. The firm had revenue of $4.28 billion for the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The business’s revenue was up 41.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.46 EPS. Equities analysts anticipate that Becton Dickinson and Co will post 11.01 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 28th. Shareholders of record on Friday, September 7th were issued a $0.75 dividend. The ex-dividend date was Thursday, September 6th. This represents a $3.00 annualized dividend and a yield of 1.23%. Becton Dickinson and’s dividend payout ratio is currently 31.65%.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Recommended Story: How to Invest in an Index Fund
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.